Followers | 210 |
Posts | 11026 |
Boards Moderated | 1 |
Alias Born | 04/20/2011 |
Thursday, March 24, 2016 12:18:51 PM
NEW YORK, NY / ACCESSWIRE / March 24, 2016 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has issued an update note on BioSig Technologies, Inc. (BSGM).
The report is available here: BSGM March 2016 Update Note. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack's. The report will be available on these platforms. The firm also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.
"In our opinion, it appears that BioSig's relationship with the Mayo Clinic - a prestigious industry partner - is strong and deepening. Earlier this month, for example, Ammar Killu, MBBS of the Mayo Clinic in Rochester, presented pre-clinical data from a series of studies at the Mayo Clinic during 2015 at the 13th International Dead Sea Symposium on Innovations in Cardiac Arrhythmias and Device Therapy at the David Intercontinental Convention Center in Tel Aviv. The presentation was entitled Enhanced Electrophysiology Recording Improves Signal Acquisition and Differentiation and featured work done utilizing Pure EP™ technology in work done in pre-clinical studies by Dr. Samuel Asirvatham and his team. BioSig has indicated that it expects at least one Mayo study to be published in a high profile medical journal during 1H16E, which we reason has the potential to attract the attention of both investors and industry leaders," stated Ajay Tandon, CEO of SeeThruEquity. "We are maintaining our 12-month price target of $3.53 per share."
http://finance.yahoo.com/news/seethruequity-issues-biosig-technologies-inc-132800360.html
I am a trader, only a trader. my posts are my opinion and are
not for sale. I do my DD, I advise you to do yours. My posts
are not recommendations to buy or sell. I have never and
will not accept payment to post on any stock. So don't ask.
Recent BSGM News
- BioSig Technologies, Inc. Announces New Appointments to its Now Fully Constituted Board of Directors, which is Comprised of 5 Board Members, 3 Independent • GlobeNewswire Inc. • 05/03/2024 04:22:00 PM
- BioSig Technologies, Inc. Appoints Mr. Anthony Amato to Position of Chief Executive Officer, Effective Immediately • GlobeNewswire Inc. • 04/30/2024 06:03:14 PM
- BioSig Engages Consulting Firm for Business Model Strategies • GlobeNewswire Inc. • 04/04/2024 03:35:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 01:00:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 01:04:14 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 02:00:37 PM
- BioSig Announces Reduction of its Workforce • GlobeNewswire Inc. • 02/20/2024 03:00:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 08:31:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2024 01:35:41 PM
- BioSig’s PURE EP™ Platform with New Near Field Tracking Algorithm Surpasses 100 Patient Cases • GlobeNewswire Inc. • 02/06/2024 01:30:00 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 02/02/2024 10:18:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 10:25:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/31/2024 09:05:24 PM
- BioSig Announces Reverse Stock Split • GlobeNewswire Inc. • 01/31/2024 04:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2024 01:52:08 PM
- BioSig Announces Cost Reductions to Improve its Financial Standing and Shifts its Core Strategy • GlobeNewswire Inc. • 01/30/2024 01:30:00 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 01/16/2024 09:15:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/12/2024 10:28:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 04:00:29 PM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 01/05/2024 09:16:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 09:05:45 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/29/2023 06:37:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:30:30 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/28/2023 09:05:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/22/2023 09:30:32 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM